drugset / Trial / NCT03185169

GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors

NCT03185169

Phase 0 Terminated 14 enrolled Alta Bates Summit Medical Center
NaSingle-groupOpen-labelTreatment

Summary

The impact of treatment for GSM on the quality of life will be examined for postmenopausal women (defined as last menstrual period \> 1 year ago or 6 months ago with FSH \>40) who have been diagnosed with breast cancer.

Timeline

Start
2016-11-18
Primary completion
2018-07-23
Completion
2018-07-23

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Coconut oil Unknown Topical
Subject Replens Unknown Other